BIOSPECIFICS TECHNOLOGIES CORP
BIOSPECIFICS TECHNOLOGIES CORP (BSTC): 1 pipeline candidate · ~81 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
80.6 months
D/E 0.01 · 0% dilution
Lead: Phase 1
1 candidate
N/A
N/A
A transparent, data-derived signal for BIOSPECIFICS TECHNOLOGIES CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$2.9M
Quarterly Burn
$3.2M
Runway
80.6 mo
Revenue
$11.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| xiaflex | Phase 1 |
Frequently asked questions
How many drug candidates are in BIOSPECIFICS TECHNOLOGIES CORP's pipeline?
BIOSPECIFICS TECHNOLOGIES CORP (BSTC) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is BIOSPECIFICS TECHNOLOGIES CORP's lead drug candidate?
BIOSPECIFICS TECHNOLOGIES CORP's most advanced tracked candidate is xiaflex (Phase 1) for Uterine fibroids.
What is BIOSPECIFICS TECHNOLOGIES CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BIOSPECIFICS TECHNOLOGIES CORP has approximately 80.6 months of cash runway.
Who is the CEO of BIOSPECIFICS TECHNOLOGIES CORP?
Joseph Truitt Interim is the chief executive officer of BIOSPECIFICS TECHNOLOGIES CORP (BSTC).
Get the full picture on BIOSPECIFICS TECHNOLOGIES CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.